Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy?

Huijgen, Nicole A.; Ridder, Maria A. J. de; Verhamme, Katia; Dohle, Gert R.; Vanrolleghem, Ann M.; Sturkenboom, Miriam; Laven, Joop S.E.; Steegers‐Theunissen, R.P.M.

doi:10.1016/j.fertnstert.2016.09.010

Cited by 17 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, a case–control study conducted by Huijgen et al concluded that the use of proton pump inhibitors in the period 6–12 months preceding seminal fluid analysis was found to be correlated with a threefold higher risk of low total motile sperm count (Huijgen et al, ). These findings suggest that a long‐term increase in stomach acidity may result in a reduction of semen quality, and hence the fertilising ability (Huijgen et al, ). Actually, this study was a case–control study of a population‐based registry (data from between 1996 and 2013), and comprising 2,473 human males from couples planning pregnancy, and some of them ( n = 241) with a low total motile sperm count.…”

Section: Discussionmentioning

confidence: 96%

Omeprazole does not alter human sperm motility, viability or DNA integrity in vitro

Banihani

Al‐khawalde

2019

Andrologia

View full text Add to dashboard Cite

The effect of omeprazole, a commonly used drug belongs to proton--pump inhibitor class, on human sperm function is still undetermined. Here, we hypothesised that addition of omeprazole to the ejaculated human semen may affect sperm parameters, and hence sperm function. Therefore, we assessed the in vitro effect of omeprazole on human sperm motility, viability and DNA integrity. Sixty-six normozoospermic semen samples were collected randomly from men who attended the andrology laboratory at King Abdullah University Hospital. Sperm motility, viability and DNA breaks were assessed in the presence (1-hr incubation at 37°C) of omeprazole at 5, 10, 20 and 50 µM compared to control (0 µM). None of the examined sperm parameters, at any tested omeprazole concentration, showed significant difference (p > 0.05) compared with the control. In conclusion, omeprazole at 5, 10, 20 and 50 µM does not alter human sperm motility, viability or DNA integrity in vitro. K E Y W O R D SDNA integrity, human spermatozoa, motility, omeprazole, viability How to cite this article: Ali Banihani S, Al-khawalde A-AA.Omeprazole does not alter human sperm motility, viability or DNA integrity in vitro. Andrologia. 2019;51:e13260. https://doi.

show abstract

Section: Discussionmentioning

confidence: 96%

Omeprazole does not alter human sperm motility, viability or DNA integrity in vitro

Banihani

Al‐khawalde

2019

Andrologia

View full text Add to dashboard Cite

show abstract

“… 5 In contrast, however, PPI use was recently linked to lower total motile sperm count (TMSC) in couples planning for pregnancy. 6 Understanding the effects of PPIs on semen is important in counseling subfertile men, considering the high rates of PPI use in the general population. Given the scarcity of evidence and the controversies in the literature, we aimed to assess the effects of PPI use on semen parameters using data from a large population of subfertile men.…”

Section: Introductionmentioning

confidence: 99%

Proton-pump inhibitor use does not affect semen quality in subfertile men

et al. 2018

View full text Add to dashboard Cite

Proton-pump inhibitors (PPIs) are among the most widely used drugs worldwide. PPI use has recently been linked to adverse changes in semen quality in healthy men; however, the effects of PPI use on semen parameters remain largely unknown specifically in cases with male factor infertility. We examined whether PPI use was associated with detrimental effects on semen parameters in a large population of subfertile men. We retrospectively reviewed data from 12 257 subfertile men who had visited our fertility clinic from 2003 to 2013. Patients who reported using any PPIs for >3 months before semen sample collection were included; 7698 subfertile men taking no medication served as controls. Data were gathered on patient age, medication use, and conventional semen parameters; patients taking any known spermatotoxic medication were excluded. Linear mixed-effect regression models were used to test the effect of PPI use on semen parameters adjusting for age. A total of 248 patients (258 samples) used PPIs for at least 3 months before semen collection. In regression models, PPI use (either as the only medication or when used in combination with other nonspermatotoxic medications) was not associated with statistically significant changes in semen parameters. To our knowledge, this is the largest study to compare PPI use with semen parameters in subfertile men. Using PPIs was not associated with detrimental effects on semen quality in this retrospective study.

show abstract

“…Miscarriage, proliferative changes, increased levels of chromogranin A, increased levels of fibroblast growth factor 2, chills, cardiovascular events (myocardial infarction, heart failure, stroke, ischemic stroke, pulmonary embolism and thrombosis), scarlet fever, hyperglycemia, mononucleosis infection, gastrointestinal bleeding, nasopharyngitis, otitis media, loss of libido, rhinitis, dementia, metabolic syndrome and hepatic steatosis, low sperm motility, increased risk of fibrosis progression, cirrhosis, hepatic decompensation and development of hepatocellular carcinoma. [44][45][46][47][48]60,[65][66][67] DI (n = 6)…”

Section: Discussionmentioning

confidence: 99%

“…Although most of the adverse events reported were already known, unexpected events such as dementia, 44 low-motility sperm, 46 miscarriage, proliferative changes, 5 increased levels of chromogranin A, 79 increased levels of fibroblast growth factor 2, 72 chills, cardiovascular events (myocardial infarction, heart failure, stroke, ischemic stroke, pulmonary embolism and thrombosis), 47 scarlet fever, hyperglycemia, mononucleosis infection, gastrointestinal bleeding, nasopharyngitis, otitis media, loss of libido and rhinitis have also been identified. 4,[65][66][67]102 Because the associations between these adverse events and use of omeprazole are not fully understood, there is a need to carry out further studies to investigate the relationships between omeprazole and these events.…”

Section: Discussionmentioning

confidence: 99%

Safety assessment of omeprazole use: a review

2018

View full text Add to dashboard Cite

BACKGROUND: Risks regarding hospital admission due to adverse drug reactions and drug interactions from use of omeprazole have been reported. The question guiding the present review was "Which adverse events occur in patients using omeprazole in a Food and Drug Administration-approved and/or off-label manner?" It was also proposed to evaluate the safety of use of omeprazole. DESIGN AND SETTING: Qualitative narrative review with critical evaluation, in a public university. METHODS: The PubMed, SCOPUS, LILACS, SciELO, EMBASE and EBSCO databases were searched on July 31, 2018. Studies evaluating adverse events were screened. RESULTS: 72 articles were included, among which 58 reported on adverse drug events (47, adverse drug reactions; 5, drug interactions; and 6, situations of ineffectiveness). 28 adverse drug reactions not described in compendia and drug leaflets were described in these studies: myocardial infarction (6); stroke (2); spontaneous abortion (1); proliferative changes (1); chills (1); heart failure (1); thrombosis (2); and dementia (1), among others. Severe adverse reactions, for instance cardiac problems, Steven-Johnson syndrome and proliferative changes, were identified. The antiplatelet effects of drugs such as clopidogrel, in patients who underwent heart-related surgery, increased the risk of developing cardiac problems, such as cardiovascular death, myocardial infarction and stroke. In newly transplanted patients, decreased absorption of mycophenolate mofetil occurred, thus leading to rejection of transplanted organs. CONCLUSION: Use of omeprazole should be monitored primarily in patients with heart disorders using antiplatelet agents concomitantly, and in newly transplanted patients using mycophenolic acid, in order to avoid serious adverse reactions.

show abstract

Are proton-pump inhibitors harmful for the semen quality of men in couples who are planning pregnancy?

Cited by 17 publications

References 29 publications

Omeprazole does not alter human sperm motility, viability or DNA integrity in vitro

Omeprazole does not alter human sperm motility, viability or DNA integrity in vitro

Proton-pump inhibitor use does not affect semen quality in subfertile men

Safety assessment of omeprazole use: a review

Contact Info

Product

Resources

About